Aimmune Therapeutics (NASDAQ:AIMT) – Analysts at Wedbush raised their Q1 2018 earnings per share estimates for Aimmune Therapeutics in a research report issued on Wednesday, March 14th, according to Zacks Investment Research. Wedbush analyst L. Moussatos now expects that the biotechnology company will earn ($0.72) per share for the quarter, up from their prior forecast of ($0.73). Wedbush has a “Outperform” rating and a $72.00 price objective on the stock. Wedbush also issued estimates for Aimmune Therapeutics’ Q2 2018 earnings at ($0.73) EPS, Q3 2018 earnings at ($0.73) EPS, Q4 2018 earnings at ($0.74) EPS, FY2018 earnings at ($2.92) EPS, FY2019 earnings at ($2.63) EPS, FY2020 earnings at ($0.06) EPS, FY2021 earnings at $3.46 EPS and FY2022 earnings at $9.93 EPS.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.09).
A number of other equities research analysts also recently commented on the stock. Piper Jaffray set a $62.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 5th. ValuEngine upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Credit Suisse Group set a $47.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, March 5th. Roth Capital raised their price objective on shares of Aimmune Therapeutics from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, March 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $64.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, March 5th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Aimmune Therapeutics presently has a consensus rating of “Buy” and an average target price of $57.22.
NASDAQ:AIMT traded down $0.20 during mid-day trading on Monday, reaching $31.42. The stock had a trading volume of 588,033 shares, compared to its average volume of 989,641. The company has a market cap of $1,758.28, a P/E ratio of -12.04 and a beta of -0.38. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $42.00.
Several hedge funds have recently bought and sold shares of the company. Carillon Tower Advisers Inc. acquired a new position in shares of Aimmune Therapeutics during the 4th quarter worth approximately $58,838,000. Alliancebernstein L.P. raised its position in shares of Aimmune Therapeutics by 109.5% during the 4th quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock worth $52,959,000 after purchasing an additional 731,927 shares during the last quarter. Citadel Advisors LLC raised its position in shares of Aimmune Therapeutics by 3,092.5% during the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after purchasing an additional 542,111 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of Aimmune Therapeutics during the 4th quarter worth approximately $18,702,000. Finally, Highland Capital Management LP acquired a new position in shares of Aimmune Therapeutics during the 4th quarter worth approximately $5,663,000. Institutional investors own 65.92% of the company’s stock.
In other news, insider Mary M. Rozenman sold 6,592 shares of Aimmune Therapeutics stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $35.36, for a total transaction of $233,093.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick G. Enright purchased 15,593 shares of Aimmune Therapeutics stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $32.00 per share, with a total value of $498,976.00. Following the completion of the transaction, the director now owns 22,869 shares in the company, valued at approximately $731,808. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 58,093 shares of company stock valued at $1,858,976 and have sold 52,162 shares valued at $2,020,890. 24.56% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Wedbush Analysts Raise Earnings Estimates for Aimmune Therapeutics (AIMT)” was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://macondaily.com/2018/04/12/aimmune-therapeutics-inc-aimt-forecasted-to-earn-q1-2018-earnings-of-0-72-per-share-updated-updated-updated.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.